Evidence map›Paper›PMID 39959285›Full record

ArticleBio-protocol2025

High-resolution Cryo-EM Structure Determination of a-Synuclein-A Prototypical Amyloid Fibril.

Juan C Sanchez, Joshua A Pierson, Collin G Borcik, Chad M Rienstra, Elizabeth R Wright

Abstract read
In one paragraph

Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. bioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. bioRxiv : the preprint server for biology · 2026
    Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Juan C SanchezDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA.
Joshua A PiersonDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA.
Collin G BorcikDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA.
Chad M RienstraDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA.
Elizabeth R WrightDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA.

Funding

The Midwest Center for Cryo-Electron TomographyU24GM139168 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI WRIGHT, ELIZABETH R · 2020 to 2025
$41.7M
Biotechnology Training ProgramT32GM135066 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI SCOTT M. COYLE, BRIAN G FOX · 2020 to 2026
$7.0M
Technologies for Solid-State NMR Data CollectionP41GM136463 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI WESTLER, WILLIAM MILO · 2021 to 2025
$6.4M
Structural Biology of Alpha-Synuclein in Lewy Body DementiaRF1NS110436 · NINDS · WASHINGTON UNIVERSITY · PI KOTZBAUER, PAUL T, RIENSTRA, CHAD M · 2023 to 2023
$4.2M
Structural Biology and Biophysics of Alpha-Synuclein Fibrils by Solid-State NMRF32GM149118 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BORCIK, COLLIN GRIFFIN · 2023 to 2024
$143k
NIGMS NIH HHS F32 GM149118NIGMS NIH HHS P41 GM136463NIGMS NIH HHS T32 GM135066NIGMS NIH HHS U24 GM139168NINDS NIH HHS RF1 NS110436
6 · The paper itself

Abstract

The physiological role of a-synuclein (a-syn), an intrinsically disordered presynaptic neuronal protein, is believed to impact the release of neurotransmitters through interactions with the SNARE complex. However, under certain cellular conditions that are not well understood, a-syn will self-assemble into β-sheet-rich fibrils that accumulate and form insoluble neuronal inclusions. Studies of patient-derived brain tissues have concluded that these inclusions are associated with Parkinson's disease, the second most common neurodegenerative disorder, and other synuclein-related diseases called synucleinopathies. In addition, repetitions of specific mutations to the SNCA gene, the gene that encodes a-syn, result in an increased disposition for synucleinopathies. The latest advances in cryo-EM structure determination and real-space helical reconstruction methods have resulted in over 60 in vitro structures of a-syn fibrils solved to date, with a handful of these reaching a resolution below 2.5 Å. Here, we provide a protocol for a-syn protein expression, purification, and fibrilization. We detail how sample quality is assessed by negative stain transmission electron microscopy (NS-TEM) analysis and followed by sample vitrification using the Vitrobot Mark IV vitrification robot. We provide a detailed step-by-step protocol for high-resolution cryo-EM structure determination of a-syn fibrils using RELION and a series of specialized helical reconstruction tools that can be run within RELION. Finally, we detail how ChimeraX, Coot, and Phenix are used to build and refine a molecular model into the high-resolution cryo-EM map. This workflow resulted in a 2.04 Å structure of a-syn fibrils with excellent resolution of residues 36-97 and an additional island of density for residues 15-22 that had not been previously reported. This workflow should serve as a starting point for individuals new to the neurodegeneration and structural biology fields. Together, this procedure lays the foundation for advanced structural studies of a-syn and other amyloid fibrils. Key features • In vitro fibril amplification method yielding twisting fibrils that span several micrometers in length and are suitable for cryo-EM structure determination. • High-throughput cryo-EM data collection of neurodegenerative fibrils, such as alpha-synuclein. • Use of RELION implementations of helical reconstruction algorithms to generate high-resolution 3D structures of a-synuclein fibrils. • Brief demonstration of the use of ChimeraX, Coot, and Phenix for molecular model building and refinement.

Indexed as

Alpha-synucleinAmyloid proteinsCryo-EMHelical reconstructionNeurodegenerationVitrification

Identifiers

PMID39959285
PMCPMC11825309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.